Email
Password
Remember meForgot password?
    Log in with Twitter
Press Release

Breast Cancer Is Only Pharmaceutical Pipeline with over 1000 Drugs in Development

Market Research Reports, Inc. has announced the addition of “Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes” research report to their website www.MarketResearchReports.com

This press release was orginally distributed by SBWire

Lewes, DE -- (SBWIRE) -- 03/24/2016 -- The breast cancer treatment pipeline's exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider Publisher.

The company's latest report states that factors driving such innovation and potential for breakthrough drugs include a very large and growing patient pool, a well-established market with multiple unmet needs, and a robust understanding of the disease pathophysiology, facilitating the development of novel compounds that may fill such needs.

Senior Analyst explains: "Breast cancer has the largest product pipeline in the pharmaceutical industry, and its significant patient population and successful commercialization of drugs such as Herceptin have attracted a great deal of R&D investment.

"The sheer number of first-in-class products in development reflects a deepening scientific understanding of the underlying pathophysiology of breast cancer and a growing list of molecules that have been implicated in the initiation and progression of the disease.

"Although the development of products for novel molecular targets is risky, as their role in disease pathophysiology is often poorly characterized, the breast cancer pipeline also has the potential to yield therapies that outperform existing products and mechanisms of action."

While the cure rate for early-stage breast cancer is currently high, and the safety and tolerability profiles of existing monoclonal Antibodies (mAbs) are strong, more advanced forms of the disease, such as metastatic cancer, are not so treatable.

Senior Analyst explains: "Due to the highly complex and polygenic nature of breast cancer, it is unlikely that the inhibition of a single target will be sufficient to substantially improve the prognosis in the clinic.

"However, it is far more likely that the concurrent use of multiple targeted therapies, along with other available modes of therapy, will be able to do this, which will positively change the clinical landscape."

Frontier Pharma: Breast Cancer – First-in-Class Innovation Clustered Around Growth Factor Signalling Processes report provides analysis of the breast cancer treatment pipeline, stratified by stage of development, molecule type and molecular target. It includes information on the current clinical and commercial landscape, and the composition of the breast cancer therapeutics market in terms of dominant molecule types and targets, as well as highlighting current unmet needs.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher's team of industry experts.

For more information Visit at: http://www.marketresearchreports.com/gbi-research/frontier-pharma-breast-cancer-first-class-innovation-clustered-around-growth-factor

Find all Oncology Reports at: http://www.marketresearchreports.com/oncology

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions

For more information on this press release visit: http://www.sbwire.com/press-releases/breast-cancer-is-only-pharmaceutical-pipeline-with-over-1000-drugs-in-development-675264.htm

Media Relations Contact

Sudeep Chakravarty
GM - Operations
Market Research Reports, Inc.
Telephone: 302-703-7787
Email: Click to Email Sudeep Chakravarty
Web: http://www.marketresearchreports.com/gbi-research/frontier-pharma-breast-cancer-first-class-innovation-clustered-around-growth-factor

Latest News
Top News